The FDA is now advising manufacturers to develop the 2024-2025 COVID-19 vaccines using the KP.2 strain for the formula, the agency announced June 13.The update comes just one week after an FDA committee voted unanimously June 5 on the 2024-2025 COVID-19 vaccine makeup, recommending it should be one that targets the monovalent JN.1-lineage. Following the […]
